

ATHEROGENICS INC  
Form 8-K  
January 04, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **January 3, 2005**

**ATHEROGENICS, INC.**  
(Exact Name of Registrant as Specified in its Charter)

|   |   |   |
|---|---|---|
| <b>Georgia</b><br>(State or other jurisdiction<br>of incorporation) | <b>0-31261</b><br>(Commission<br>File Number) | <b>58-2108232</b><br>(I.R.S. Employer<br>Identification Number) |
|---|---|---|

**8995 Westside Parkway**  
**Alpharetta, GA 30004**  
(Address of principal executive offices)

Registrant's telephone number, including area code **(678) 336-2500**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On January 3, 2005, AtheroGenics, Inc. issued a press release to provide an update on its AGI-1067 clinical program for the treatment of atherosclerosis in patients with coronary heart disease. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

The following exhibit is attached to this current report on Form 8-K as Exhibit 99.1.

| <u>Exhibit</u><br><u>No.</u> | <u>Description</u>                     |
|------------------------------|--|
| 99.1                         | - Press Release dated January 3, 2005. |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**ATHEROGENICS, INC.**

Date: January 4, 2005

/s/MARK P. COLONNESE  
Mark P. Colonnese  
Senior Vice President of Finance and  
Administration and Chief Financial Officer

**EXHIBIT INDEX**

| <u>Exhibit<br/>No.</u> | <u>Description</u>                     |
|------------------------|--|
| 99.1                   | - Press Release dated January 3, 2005. |